Discovery of novel Akt1 inhibitors by an ensemble-based virtual screening method, molecular dynamics simulation, and

Wen Zhang1, Mei-Ling Hu1, Xiu-Yun Shi1

  • 1College of Life Science, Northwest Normal University, Lanzhou, 730070, Gansu, People's Republic of China.

Molecular Diversity
|January 19, 2024
PubMed

Insights

Researchers identified a novel compound, Hit9, as a potent inhibitor of Akt1 (also known as Protein Kinase B), a key target in cancer therapy. This discovery offers a promising new avenue for developing effective cancer treatments.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Akt1 is a crucial regulator of cancer cell growth and survival.
  • Inhibiting Akt1 activity can induce cancer cell apoptosis and suppress tumor progression.

Purpose of the Study:

  • To develop a virtual screening platform for identifying novel Akt1 inhibitors.
  • To discover and characterize potential lead compounds for Akt1-targeted cancer therapy.

Main Methods:

  • A multilayer virtual screening approach combining pharmacophore modeling, 3D-QSAR, molecular docking, and deep learning.
  • Identification of 17 potential Akt1 inhibitors from three databases.
  • In vitro evaluation of compound inhibitory activity and molecular dynamics simulations.

Main Results:

  • The compound Hit9 demonstrated the most significant inhibitory activity against Akt1 (33.08% inhibition at 1 μM).
  • Molecular dynamics simulations confirmed a stable and compact complex formation between Hit9 and Akt1.
  • Hit9 interacted with key Akt1 residues via hydrophobic, electrostatic, and hydrogen bonding interactions, inducing conformational changes in the active site.

Conclusions:

  • Hit9, with its novel scaffold, represents a promising lead compound for the development of new Akt1 inhibitors.
  • This compound holds potential for treating various cancers overexpressing Akt1.